Articles related to MUTATIONS

The prevalence of HRR deficiencies has been found to be as high as 20% to 30% in patients with mCRPC, a significantly higher rate than that in patients with localized disease.

The combination of imlunestrant plus abemaciclib demonstrated significant progression-free survival benefit across all subgroups, including patients with prior CDK4/6 inhibitor use and those with visceral metastases.

Subcutaneous administration of amivantamab demonstrated noninferiority to IV delivery while potentially offering enhanced patient convenience and reduced healthcare system burden.

The inavolisib-based regimen more than doubled progression-free survival in PIK3CA-mutated breast cancers, offering a new standard of care for this challenging patient population.

Osimertinib significantly improved progression-free survival in patients with unresectable stage III EGFR-mutant NSCLC after chemoradiotherapy, with a hazard ratio of 0.16 compared to placebo.